Format

Send to

Choose Destination
Curr Opin Hematol. 2008 Jul;15(4):352-8. doi: 10.1097/MOH.0b013e328303e15d.

MicroRNAs in normal and malignant hematopoiesis.

Author information

1
Division of Hematology and Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA.

Abstract

PURPOSE OF REVIEW:

The discovery of a novel class of gene regulators, named microRNAs, has changed the landscape of human genetics. In hematopoiesis, recent work has improved our understanding of the role of microRNAs in hematopoietic differentiation and leukemogenesis.

RECENT FINDINGS:

Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92). Distinctive miRNA signatures have been described in association with cytogenetics and outcome in acute myeloid leukemia.

SUMMARY:

There is now strong evidence that miRNAs modulate not only hematopoietic differentiation and proliferation but also activity of hematopoietic cells, in particular those related to immune function. Extensive miRNA deregulation has been observed in leukemias and lymphomas and mechanistic studies support a role for miRNAs in the pathogenesis of these disorders.

PMID:
18536574
DOI:
10.1097/MOH.0b013e328303e15d
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center